Single vein resection in surgery for pancreatic ductal carcinoma as a criterion of resectability

Single vein resection in surgery for pancreatic ductal carcinoma as a criterion of resectability

Автор: Chichevatov D.A., Kalentjev V.V., Glukhov A.E.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Клинические исследования

Статья в выпуске: 4 т.21, 2022 года.

Бесплатный доступ

Background. pancreatic ductal carcinoma (pdc) with involvement of the superior mesenteric vein (smV) or/and portal vein (pV) remains a discussible subject. We have evaluated vein invasion as a criterion of borderline resectability and long-term outcome. material and methods. in our center, 68 patients underwent either 65 standard pancreatoduodenal resections or 3 pancreatoduodenectomies for pdc. Resection of smV/pV was performed in 18 cases (26.5 %). three patients received neoadjuvant chemotherapy (Nact), and adjuvant chemotherapy (act) was assigned to 37 patients (54.4 %). Results. morbidity (42.0 vs 50.0 %, р=0.590) and mortality rates (4.0 vs 16.7 %, р=0.111) had no significant differences in groups of standard and angioplasty operations respectively. act was completed in 10 (16.7 %) patients only. there was true vein invasion in 12 of 18 patients with vein resection. рN+ (р=0.012) and angioplasty by itself (р

Еще

Carcinoma, pancreatic ductal, portal vein, angioplasty

Короткий адрес: https://sciup.org/140295748

IDR: 140295748   |   DOI: 10.21294/1814-4861-2022-21-4-25-31

Список литературы Single vein resection in surgery for pancreatic ductal carcinoma as a criterion of resectability

  • Versteijne E., Suker M., Groothuis K., Akkermans-Vogelaar J.M., Besselink M.G., Bonsing B.A., Buijsen J., Busch O.R., Creemers G.M., van Dam R.M., Eskens F.A.L.M., Festen S., de Groot J.W.B., Groot Koer-kamp B., de Hingh I.H., Homs M.Y.V., van Hooft J.E., Kerver E.D., Luelmo S.A. C., Neelis K.J., Nuyttens J., Paardekooper GM.R.M, Patijn G.A., van der Sangen M.J.C., de Vos-Geelen J., Wilmink J.W., ZwindermanA.H., Punt C.J., van Eijck C.H., van Tienhoven G.; Dutch Pancreatic Cancer Group. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020; 38(16): 1763-73. doi: 10.1200/JCO.19.02274.
  • Klaiber U., Hackert T. Conversion Surgery for Pancreatic Cancer-The Impact of Neoadjuvant Treatment. Front Oncol. 2020; 9: 1501. doi: 10.3389/fonc.2019.01501.
  • Tang K., Lu W., Qin W., Wu Y. Neoadjuvant therapy for patients with borderline resectable pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. Pancreatology. 2016; 16(1): 28-37. doi: 10.1016/j.pan.2015.11.007.
  • Oba A., Ho F., Bao Q.R., Al-Musawi M.H., Schulick R.D., Del Chia-ro M. Neoadjuvant Treatment in Pancreatic Cancer. Front Oncol. 2020; 10: 245. doi: 10.3389/fonc.2020.00245.
  • Schorn S., Demir I.E., Reyes C.M., Saricaoglu C., Samm N., Schirren R., TieftrunkE., HartmannD., Friess H., Ceyhan G.O. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis. Cancer Treat Rev. 2017; 55: 96-106. doi: 10.1016/j.ctrv.2017.03.003.
  • Assifi M.M., Lu X., Eibl G., Reber H.A., Li G., Hines O.J. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011; 150(3): 466-73. doi: 10.1016/j.surg.2011.07.006.
  • Gillen S., Schuster T., Meyer Zum Büschenfelde C., Friess H., Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010; 7(4). doi: 10.1371/journal.pmed.1000267.
  • CasolinoR., Braconi C., Malleo G., Paiella S., Bassi C., MilellaM., Dreyer S.B., Froeling F.E.M., Chang D.K., Biankin A.V., Golan T. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Ann Oncol. 2021; 32(2): 183-96. doi: 10.1016/j. annonc.2020.11.013.
  • Dumont R., PuleoF., Collignon J., MeurisseN., Chavez M., SeidelL., Gast P., Polus M., Loly C., Delvenne P., Meunier P., Hustinx R., Deroover A., Detry O., Louis E., Martinive P., Van Daele D. A single center experience in resectable pancreatic ductal adenocarcinoma: the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update. Acta Gastroenterol Belg. 2017; 80(4): 451-61. Erratum in: Acta Gastroenterol Belg. 2018; 81(2): 358.
  • Rahman S.H., UrquhartR., MolinariM. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol. 2017; 9(12): 457-65. doi: 10.4251/wjgo.v9.i12.457.
  • Delpero J.R., Sauvanet A. Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019. Front Oncol. 2020; 10: 40. doi: 10.3389/fonc.2020.00040.
  • Ferrone C.R., Marchegiani G., Hong T.S., RyanD.P., Deshpande V., McDonnell E.I., Sabbatino F., Santos D.D., Allen J.N., Blaszkowsky L.S., Clark J.W., Faris J.E., Goyal L., Kwak E.L., Murphy J.E., Ting D.T., Wo J.Y., Zhu A.X., Warshaw A.L., Lillemoe K.D., Fernández-del Castillo C. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015; 261(1): 12-7. doi: 10.1097/ SLA.0000000000000867.
  • Wittel U.A., Lubgan D., GhadimiM., Belyaev O., Uhl W., Bechs-tein W.O., Grützmann R., Hohenberger W.M., Schmid A., Jacobasch L., CronerR.S., Reinacher-Schick A., Hopt U.T., PirklA., OettleH., FietkauR., GolcherH. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial. BMC Cancer. 2019; 19(1): 979. doi: 10.1186/s12885-019-6148-5.
  • Katz M.H., Pisters P.W., Evans D.B., Sun C.C., Lee J.E., Fleming J.B., Vauthey J.N., Abdalla E.K., Crane C.H., Wolff R.A., Varad-hachary G.R., Hwang R.F. Borderline resectable pancreatic cancer: the importance ofthis emerging stage of disease. J Am Coll Surg. 2008; 206(5): 833-46. doi: 10.1016/j.jamcollsurg.2007.12.020.
  • WangX., Demir I.E., Schorn S., Jäger C., Scheufele F., Friess H., Ceyhan G.O. Venous resection during pancreatectomy for pancreatic cancer: a systematic review. Transl Gastroenterol Hepatol. 2019; 4: 46. doi: 10.21037/tgh.2019.06.01.
  • Bockhorn M., Uzunoglu F.G., Adham M., Imrie C., Milicevic M., SandbergA.A., AsbunH.J., Bassi C., BüchlerM., CharnleyRM., ConlonK., CruzL.F., Dervenis C., Fingerhutt A., FriessH., GoumaD.J., Hartwig W., LillemoeK.D., MontorsiM., Neoptolemos J.P., Shrikhande S. V., TakaoriK., Traverso W., Vashist Y.K., Vollmer C., Yeo C.J., Izbicki J.R.; International Study Group of Pancreatic Surgery. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014; 155(6): 977-88. doi: 10.1016/j. surg.2014.02.001.
  • Lopez N.E., Prendergast C., Lowy A.M. Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol. 2014; 20(31): 10740-51. doi: 10.3748/wjg.v20.i31.10740.
  • Nakao A. Selection and outcome of portal vein resection in pancreatic cancer. Cancers (Basel). 2010; 2(4): 1990-2000. doi: 10.3390/ cancers2041990.
  • Park M.Y., Lee W, Kwon J., Song K.B., Hwang D.W., Lee J.H., Kim S.C. Comparison of perioperative outcomes in pancreatic head cancer patients following either a laparoscopic or open pancreaticoduodenectomy with a superior mesenteric artery first approach. Ann Hepatobiliary Pancreat Surg. 2021; 25(3): 358-65. doi: 10.14701/ahbps.2021.25.3.358.
  • Kishi Y., Nara S., Esaki M., Hiraoka N., Shimada K. Feasibility of resecting the portal vein only when necessary during pancreatoduodenectomy for pancreatic cancer. BJS Open. 2019; 3(3): 327-35. doi: 10.1002/bjs5.50130.
Еще
Статья научная
SciUp 2024 © 2024 ©